Q Biomed Financials
This page shows Q Biomed (QBIO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Q BioMed’s visible mechanic is balance-sheet survival: tiny revenue, heavy overhead, and capital-structure dependence overshadow operating progress.
FY2022 cash generation did not line up with the income statement: operating cash flow turned positive at$1.94M even as operating loss remained-$3.45M . With only$344K of cash against$8.13M of liabilities, that inflow looks more like a balance-sheet timing effect than evidence that the core business became self-funding.
Unit economics improved from FY2021 to FY2022, with gross margin moving from
Funding pressure shifted onto shareholders as shares outstanding jumped from 28.6M to 84.3M between FY2021 and FY2022, showing that financing actions mattered more than commercial scale. Yet year-end cash was still only
Financial Health Signals
Based on FY2022 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Q Biomed's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Q Biomed has an operating margin of -1211.7%, meaning the company retains $-1212 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses.
Q Biomed's revenue surged 45.4% year-over-year to $284K, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Q Biomed has elevated debt relative to equity (D/E of -1.76), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.
Q Biomed's current ratio of 0.01 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Q Biomed passes 3 of 9 financial strength tests. 2 of 3 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Q Biomed generates $-0.95 in operating cash flow ($1.9M OCF vs -$2.1M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
Q Biomed earns $-2.5 in operating income for every $1 of interest expense (-$3.4M vs $1.4M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Q Biomed generated $284K in revenue in fiscal year 2022. This represents an increase of 45.4% from the prior year.
Q Biomed reported -$2.1M in net income in fiscal year 2022.
Q Biomed earned $-0.08 per diluted share (EPS) in fiscal year 2022. This represents an increase of 75.8% from the prior year.
Cash & Balance Sheet
Q Biomed held $344K in cash against $0 in long-term debt as of fiscal year 2022.
Q Biomed had 84M shares outstanding in fiscal year 2022. This represents an increase of 194.4% from the prior year.
Margins & Returns
Q Biomed's gross margin was -3.2% in fiscal year 2022, indicating the percentage of revenue retained after direct costs. This is up 23.0 percentage points from the prior year.
Q Biomed's operating margin was -1211.7% in fiscal year 2022, reflecting core business profitability.
Q Biomed's net profit margin was -721.7% in fiscal year 2022, showing the share of revenue converted to profit.
Capital Allocation
Q Biomed invested $125K in research and development in fiscal year 2022. This represents a decrease of 88.3% from the prior year.
QBIO Income Statement
| Metric | Q1'23 | Q4'22 | Q3'22 | Q2'22 | Q1'22 | Q4'21 | Q3'21 | Q2'21 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $13K-52.3% | $26K-84.6% | $170K+127.1% | $75K | N/A | $46K+1.5% | $45K |
| Cost of Revenue | $3K-96.9% | $80K+20.7% | $66K-8.7% | $73K-1.6% | $74K | N/A | $74K+59.0% | $46K |
| Gross Profit | -$3K+96.3% | -$68K-68.4% | -$40K-141.1% | $98K+8673.4% | $1K | N/A | -$28K-1906.8% | -$1K |
| R&D Expenses | $3K-87.9% | $22K+6.6% | $21K+59.7% | $13K-81.2% | $69K | N/A | $202K-30.8% | $292K |
| SG&A Expenses | $440K-7.5% | $476K-33.9% | $720K-29.3% | $1.0M-7.0% | $1.1M | N/A | $1.4M-9.7% | $1.5M |
| Operating Income | -$445K | N/A | N/A | N/A | -$1.2M | N/A | N/A | N/A |
| Interest Expense | $277K+0.2% | $276K+15.2% | $240K-47.3% | $454K+9.6% | $414K | N/A | $99K+16.7% | $85K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$722K-131.3% | $2.3M+389.6% | -$795K+37.4% | -$1.3M+44.5% | -$2.3M | N/A | -$1.8M+6.3% | -$1.9M |
| EPS (Diluted) | $-0.02 | N/A | $-0.03+50.0% | $-0.06+25.0% | $-0.08 | N/A | $-0.07+12.5% | $-0.08 |
QBIO Balance Sheet
| Metric | Q1'23 | Q4'22 | Q3'22 | Q2'22 | Q1'22 | Q4'21 | Q3'21 | Q2'21 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $3.5M-1.4% | $3.5M+605.9% | $498K+5.9% | $470K-12.7% | $538K-33.5% | $809K+34.6% | $602K-23.4% | $785K |
| Current Assets | $34K-53.0% | $72K-61.0% | $186K+27.9% | $145K-27.8% | $201K-56.3% | $459K+92.2% | $239K-41.7% | $410K |
| Cash & Equivalents | $50K-85.5% | $344K+149.6% | $138K+407.3% | $27K-80.2% | $137K-60.1% | $344K+127.5% | $151K-47.9% | $290K |
| Inventory | N/A | N/A | $23K+1.1% | $22K | N/A | $22K | N/A | N/A |
| Accounts Receivable | $0-100.0% | $12K0.0% | $12K-84.5% | $74K+168.2% | $28K-65.4% | $80K+106.0% | $39K-6.1% | $41K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $9.9M+21.8% | $8.1M+5.2% | $7.7M+2.3% | $7.6M+18.7% | $6.4M+15.9% | $5.5M+52.7% | $3.6M+20.9% | $3.0M |
| Current Liabilities | $9.9M+21.8% | $8.1M+5.2% | $7.7M+2.3% | $7.6M+18.7% | $6.4M+15.9% | $5.5M+52.7% | $3.6M+20.9% | $3.0M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$6.4M-39.5% | -$4.6M+36.2% | -$7.2M-2.0% | -$7.1M-21.6% | -$5.8M-24.4% | -$4.7M-56.4% | -$3.0M-36.7% | -$2.2M |
| Retained Earnings | -$68.3M-3.4% | -$66.1M+3.4% | -$68.4M-1.2% | -$67.6M-1.9% | -$66.3M-3.4% | -$64.1M-3.3% | -$62.1M-3.0% | -$60.3M |
QBIO Cash Flow Statement
| Metric | Q1'23 | Q4'22 | Q3'22 | Q2'22 | Q1'22 | Q4'21 | Q3'21 | Q2'21 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$138K-105.2% | $2.7M+1214.6% | -$239K-117.6% | -$110K+70.8% | -$377K+75.8% | -$1.6M-85.6% | -$840K+22.5% | -$1.1M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $111K-71.3% | $388K+10.8% | $350K | $0-100.0% | $170K-90.3% | $1.8M+149.9% | $701K-25.4% | $940K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
QBIO Financial Ratios
| Metric | Q1'23 | Q4'22 | Q3'22 | Q2'22 | Q1'22 | Q4'21 | Q3'21 | Q2'21 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | -539.8%-386.9pp | -152.9%-210.2pp | 57.3%+55.9pp | 1.5% | N/A | -61.5%-58.4pp | -3.1% |
| Operating Margin | N/A | N/A | N/A | N/A | -1551.4% | N/A | N/A | N/A |
| Net Margin | N/A | 18368.3%+21394.9pp | -3026.6%-2281.2pp | -745.4%+2303.7pp | -3049.1% | N/A | -3913.3%+327.3pp | -4240.6% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -20.8%-86.3pp | 65.5%+225.1pp | -159.7%+110.7pp | -270.3%+154.7pp | -425.1% | N/A | -297.1%-54.0pp | -243.1% |
| Current Ratio | 0.000.0 | 0.01-0.0 | 0.020.0 | 0.02-0.0 | 0.03-0.1 | 0.08+0.0 | 0.07-0.1 | 0.14 |
| Debt-to-Equity | -1.54+0.2 | -1.76-0.7 | -1.070.0 | -1.07+0.0 | -1.09+0.1 | -1.17+0.0 | -1.20+0.2 | -1.36 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$4.6M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.01), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Q Biomed's annual revenue?
Q Biomed (QBIO) reported $284K in total revenue for fiscal year 2022. This represents a 45.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Q Biomed's revenue growing?
Q Biomed (QBIO) revenue grew by 45.4% year-over-year, from $196K to $284K in fiscal year 2022.
Is Q Biomed profitable?
No, Q Biomed (QBIO) reported a net income of -$2.1M in fiscal year 2022, with a net profit margin of -721.7%.
What is Q Biomed's gross margin?
Q Biomed (QBIO) had a gross margin of -3.2% in fiscal year 2022, indicating the percentage of revenue retained after direct costs of goods sold.
What is Q Biomed's operating margin?
Q Biomed (QBIO) had an operating margin of -1211.7% in fiscal year 2022, reflecting the profitability of core business operations before interest and taxes.
What is Q Biomed's net profit margin?
Q Biomed (QBIO) had a net profit margin of -721.7% in fiscal year 2022, representing the share of revenue converted into profit after all expenses.
What is Q Biomed's operating cash flow?
Q Biomed (QBIO) generated $1.9M in operating cash flow during fiscal year 2022, representing cash generated from core business activities.
What are Q Biomed's total assets?
Q Biomed (QBIO) had $3.5M in total assets as of fiscal year 2022, including both current and long-term assets.
How much does Q Biomed spend on research and development?
Q Biomed (QBIO) invested $125K in research and development during fiscal year 2022.
What is Q Biomed's current ratio?
Q Biomed (QBIO) had a current ratio of 0.01 as of fiscal year 2022, which is below 1.0, which may suggest potential liquidity concerns.
What is Q Biomed's debt-to-equity ratio?
Q Biomed (QBIO) had a debt-to-equity ratio of -1.76 as of fiscal year 2022, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Q Biomed's return on assets (ROA)?
Q Biomed (QBIO) had a return on assets of -58.4% for fiscal year 2022, measuring how efficiently the company uses its assets to generate profit.
Why is Q Biomed's debt-to-equity ratio negative or unusual?
Q Biomed (QBIO) has negative shareholder equity of -$4.6M as of fiscal year 2022, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Q Biomed's Piotroski F-Score?
Q Biomed (QBIO) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Q Biomed's earnings high quality?
Q Biomed (QBIO) has an earnings quality ratio of -0.95x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Q Biomed cover its interest payments?
Q Biomed (QBIO) has an interest coverage ratio of -2.5x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Q Biomed?
Q Biomed (QBIO) scores 17 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.